UnitedHealth Group reported first-quarter earnings that exceeded Wall Street expectations and raised its 2026 profit forecast as the healthcare giant demonstrates improved control over medical expenses while implementing operational streamlining measures.
The Minneapolis-based insurer now anticipates adjusted earnings exceeding $18.25 per share for 2026, up from its prior projection of more than $17.75 per share. The company maintained its full-year revenue guidance of greater than $439 billion.
By the Numbers
UnitedHealth posted net income of $6.28 billion, or $6.90 per share, for the quarter ended March 31, compared with $6.29 billion, or $6.85 per share, in the same period last year. Adjusted earnings reached $7.23 per share, surpassing analyst estimates.
Revenue climbed to $111.72 billion from $109.58 billion in the year-earlier quarter, with both the UnitedHealthcare insurance arm and Optum health services division exceeding sales projections.
The company’s medical benefit ratio—a key profitability metric measuring claim costs against premium revenue—improved to 83.9% from 84.8% a year earlier. The figure came in well below the 85.5% analysts had forecast, indicating stronger cost management.
Why It Matters
The results suggest UnitedHealth is making progress on persistent medical cost pressures that have challenged the insurance industry for more than two years. Insurers have faced rising expenses from patients seeking delayed post-pandemic care and high-cost specialty medications, including weight-loss drugs known as GLP-1s.
The improved cost ratio reflects what the company described as strong medical expense management and the release of reserves previously set aside for unprofitable Optum contracts, though medical costs remain “consistently elevated.”
Zoom Out
UnitedHealth is executing a turnaround strategy under new leadership that includes reducing membership, divesting its U.K. operations, investing heavily in artificial intelligence, and improving care access and transparency. The approach aims to restore profitability and reputation following operational challenges over the past two years.
The earnings report follows the Trump administration’s decision to finalize a larger-than-expected 2027 payment rate increase for Medicare Advantage plans, providing a boost to UnitedHealth and competing insurers.
What’s Next
A key question remains whether UnitedHealth will participate in the administration’s planned Medicare coverage program for obesity drugs launching next year. Insurers faced a Monday deadline to notify federal officials of their participation in the initiative, which would cover GLP-1 treatments from Eli Lilly and Novo Nordisk.
Bobby Hunter, head of the company’s government programs, said on Tuesday’s earnings call that UnitedHealth wants to find a path toward coverage but faces “notable challenges and outstanding questions” about the program’s structure. The company, as the largest Medicare Advantage provider, plays a critical role in determining the program’s viability.
“We are continuing to help simplify and modernize health care for the people and care providers we serve, bringing greater value, affordability, transparency and connectivity,” said CEO Stephen Hemsley in a statement.